Follistatin 344 Reconstitution Calculator

No. Follistatin-344 (FS-344) has no approved pharmaceutical formulation in any country; all available products are black-market injectables sold outside regulatory oversight [2,3]. Follistatin is prohibited in and out of competition under WADA category S4 [1,2]. No myostatin-pathway peptide holds FDA approval for muscle growth.

No human RCT exists. In animals: transgenic pigs expressing human FS-344 showed increased skeletal muscle mass, reduced fat accumulation, and metabolically benign liver [5,6]; AAV follistatin gene delivery increased muscle growth and strength in nonhuman primates. Mechanistically, follistatin neutralizes myostatin (GDF8), activins A/B, and GDF11. In humans, a 26-study meta-analysis found circulating follistatin did not differ between sarcopenic and healthy older adults, and exercise raises endogenous plasma follistatin ~7-fold from the liver without evidence this drives hypertrophy. Efficacy in humans is extrapolated, not demonstrated (animal).

Yes. FS-344 is a ~38 kDa glycoprotein; no oral formulation exists or would survive digestion (mechanistic). All black-market products are injectable lyophilized powders. Community use is subcutaneous or intramuscular injection after reconstitution in bacteriostatic water (community protocol).

Documented human harm: high-dose FS-344 was associated with central serous chorioretinopathy (vision-threatening subretinal fluid) in a retrospective case series (observational). Follistatin is expressed by solid tumors and implicated in proliferation, angiogenesis, immune evasion, and drug resistance; high tumor FST expression predicts poor overall survival in head and neck squamous cell carcinoma. A 2026 sports-medicine review flags "potential for serious harm" to patients given scarce human safety data.

No clinical dosing data exist. Typical community dosing is 50-100 mcg intramuscular or subcutaneous daily for 7-14 days, or 1-2 mcg/kg every other day (community protocol). None is validated; black-market products are frequently mislabeled or counterfeit, making self-reported dosing unreliable.

Independent laboratory analysis found only 9 of 17 black-market "follistatin 344" products actually contained follistatin; some substituted growth-promoting peptides such as MGF and GHRP-2 instead. All positive samples were His-tagged recombinant FS-344 with high oligomer content, an aggregation/immunogenicity concern. Third-party mass-spectrometry verification per batch is the only practical safeguard (community protocol).

Yes. Follistatin is WADA-prohibited (S4) [1,2]. A validated immunoprecipitation/Western blot method detects His-tagged black-market FS-344 in urine to ~0.1 ng/mL (10 mL sample) and ~5 ng/mL in serum (100 µL), with the His-tag permitting unambiguous differentiation from endogenous follistatin.

Same regulatory and evidence category: FS-344, BPC-157, CJC-1295, ipamorelin, and TB-500 share favorable animal repair/metabolic data, scarce rigorous human safety data, and gray-market distribution. The distinguishing risk: FS-344 directly suppresses the myostatin/activin axis, overlapping with tumor follistatin biology and drug-resistance pathways [10,11], whereas BPC-157's primary gap is absent human toxicity data rather than established oncogenic signaling.